drugset / Trial / NCT00545142

Abilify in Bipolar Disorder for 6 Weeks Treatment Effectiveness

NCT00545142

Phase 4 Completed 280 enrolled Korea Otsuka Pharmaceutical Co., Ltd.
Non-randomizedSingle-groupOpen-labelTreatment

Summary

To demonstrate the efficacy and safety of co-administration of Abilify(aripiprazole) with Depakote(divalproate) in the acute phase of 6-week treatment of acute mania in patients with bipolar disorder.

Timeline

Start
2007-10
Primary completion
2010-06
Completion
2010-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified
Subject Divalproate Unknown

Indications